Guardant Health
3100 Hanover Street
Palo Alto
California
94304
United States
246 articles about Guardant Health
-
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer
4/27/2021
Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Daiichi Sankyo, Inc. (Daiichi Sankyo) to pursue regulatory approval and commercialization of the Guardant360® CDx blood test as a companion diagnostic for Enhertu® (fam-trastuzumab deruxtecan-nxki)
-
Guardant Health to Report First Quarter Financial Results on May 6, 2021
4/12/2021
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2021 after market close on Thursday, May 6, 2021.
-
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
4/10/2021
Phase 2 trial of Amgen’s investigational KRASG12C inhibitor, sotorasib, demonstrated comparable efficacy between patients identified as KRASG12C positive using Guardant360 CDx liquid biopsy or tissue biopsy
-
Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer
4/1/2021
Guardant Health, Inc. (Nasdaq: GH) announced that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the Guardant Reveal™ liquid biopsy test for the detection and monitoring of minimal residual disease (MRD) in patients with early-stage cancer (stage II and III)
-
Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360® CDx Test
3/30/2021
Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360 ® CDx Test
-
Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
3/2/2021
Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor).
-
Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021
2/24/2021
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2020.
-
Guardant Health to Participate in Upcoming Investor Conferences - Feb 17, 2021
2/17/2021
Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the following virtual investor conferences.
-
Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer
2/16/2021
Guardant Reveal™ is industry’s first blood-only test able to detect, with 7-day turnaround time, residual disease after surgery and recurrence months earlier than current standard-of-care methods
-
Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
2/4/2021
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24, 2021.
-
Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe
1/18/2021
Guardant Health, Inc., a leading precision oncology company, and Vall d’Hebron Institute of Oncology, one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using Guardant Health’s industry-leading proprietary digital sequencing platform, at VHIO’s facility in Barcelona, Spain.
-
Guardant Health to Present Data at ASCO Gastrointestinal Cancers Symposium Showing Value of Liquid Biopsy to Advance Precision Oncology in Early to Late-Stage Colorectal Cancer
1/14/2021
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of Guardant Health’s proprietary blood tests to make a meaningful impact on patient care at the upcoming virtual 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium being held January 15-17, 2021. The presentations will co
-
Guardant Health Presents Data at San Antonio Breast Cancer Symposium Demonstrating Utility of GuardantINFORM™ Real-World Platform in Metastatic Breast Cancer
12/7/2020
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, shares new data at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) showing how its GuardantINFORM™ real-world clinical-genomic platform can be used to gain deeper insights into patients’ treatments and associated response to support the development of more effective therapies for biomarker-defined cancers
-
Guardant Health is taking Roche-owned Foundation Medicine to court over a patent dispute for their liquid biopsy technology, further heating up the rivalry between the two cancer detection companies.
-
Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering
11/17/2020
Guardant Health, Inc. announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Guardant Health, Inc. Announces Proposed Convertible Senior Notes Offering - Nov 16, 2020
11/16/2020
Guardant Health, Inc. announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Guardant Health Reports Third Quarter 2020 Financial Results
11/5/2020
Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, reported financial results for the quarter ended September 30, 2020.
-
Guardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder
10/15/2020
Guardant Health, Inc. announced the closings of an underwritten public offering of 7,700,000 shares of its common stock, which includes full exercise of the underwriter’s option to purchase 700,000 shares, at a public offering price of $102.00 per share, before deducting underwriting discounts and commissions, all of which were sold by SoftBank Investment Advisers.
-
Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder
10/7/2020
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the pricing of an underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $102.00 per share,
-
Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder
10/6/2020
Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the commencement of a proposed underwritten public offering of 7,000,000 shares of its common stock being offered for sale by SoftBank Investment Advisers